Search

everythinglearnresearchcommunity

for

Search:↓

Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.

Omalizumab can cause temporary hair loss but still works well for chronic urticaria.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Mogamulizumab can cause hair loss and skin rashes.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

Tocilizumab might be an effective treatment for COVID-19.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Tofacitinib treatment is used for teenagers with alopecia areata.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Clofazimine effectively treated ashy dermatosis in a patient.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Ixekizumab is safe for long-term use with low rates of major heart-related events.